loading page

Efficacy and safety of tamsulosin versus its combination with mirabegron in the management of benign prostatic Hyperplasia (BPH) with predominantly coexisting overactive bladder symptoms (OABS) - An open label randomised controlled clinical study.
  • +1
  • IQBAL SINGH,
  • Dibya Behera,
  • Aravind TK,
  • Sanjay Gupta
IQBAL SINGH
University College of Medical Sciences (University of Delhi) & GTB Hospital
Author Profile
Dibya Behera
University College of Medical Sciences & GTB Hospital
Author Profile
Aravind TK
Author Profile
Sanjay Gupta
Author Profile

Abstract

PURPOSE: We aim to do an efficacy-safety analysis of Mirabegron-Tamsulosin combination therapy versus tamsulosin-placebo monotherapy in a select subset of medication virgin BPH patients with coexisting predominantly overactive bladder symptoms (OABS). METHODS: After prior written informed consent and institutional ethics clearance, 80 patients of uncomplicated BPH with coexisting OABS and IPSS of >7 were computer randomized and allocated to receive therapy with either [50mg Mirabegronplus Tamsulosin 0.4 mg (Intervention arm)]or [Tamsulosin 0.4 mg plus capsule lactobacillus (Comparator arm)] once daily for a period of 8 weeks. Efficacy was evaluated using the OABS Score (OABSS), mean change in the frequency of nocturnal voiding, post void residue (PVR) and international prostate symptom score (IPSS) while safety was assessed by recording treatment emergent adverse events (TEAE). The protocol was registered prospectively with the clinical trials registry of India (CTRI/2018/12/016541). RESULTS: Significant improvements were visualised in the primary endpoint total OABS subscore (OABSS-ss) at the end of 8 weeks in the combination group (mean difference -5.62 vs -2.22p< 0.001).Similar significant improvements were seen with most of the secondary parameters such as the mean change in voiding episode/night, IPSS, IPSS-ss,OABS-ss, voided volume/micturition, Qmax, and Quality of Life (QOL) indices (p<0.001). No significant increase in PVR was observed in the Mirabegron arm and no patient developed urinary retention. The TEAE were minor, self-limiting and were managed symptomatically without any treatment discontinuity. CONCLUSION: Mirabegron was significantly efficacious and safe in ameliorating OABS induced by BPH versus placebo. This efficacy can be safely enhanced by initiating Mirabegron-Tamsulosin combination therapy from the start in medication virgin patients as opposed to the usual add on therapy protocol. This combination appeared to be superior in terms of overall safety, minimal side effects, better compliance and tolerability versus Tamsulosin monotherapy particularly in the select subset of patients of with BPH coexisting/predominant OABS.

Peer review status:ACCEPTED

07 Dec 2020Submitted to International Journal of Clinical Practice
07 Dec 2020Submission Checks Completed
07 Dec 2020Assigned to Editor
11 Dec 2020Reviewer(s) Assigned
16 Mar 2021Review(s) Completed, Editorial Evaluation Pending
22 Mar 20211st Revision Received
22 Mar 2021Submission Checks Completed
22 Mar 2021Assigned to Editor
23 Mar 2021Reviewer(s) Assigned
24 Mar 2021Review(s) Completed, Editorial Evaluation Pending
25 Mar 2021Editorial Decision: Accept